TD Cowen Has Lowered Expectations for Simulations Plus (NASDAQ:SLP) Stock Price

Simulations Plus (NASDAQ:SLP) had its price objective reduced by TD Cowen from $19.00 to $16.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “hold” rating on the technology company’s stock. TD Cowen’s price target indicates a potential upside of 22.70% from the company’s previous close.

A number of other research firms have also recently issued reports on SLP. Citigroup restated a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. BTIG Research cut Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. Zacks Research cut Simulations Plus from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. Finally, Wall Street Zen cut Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Simulations Plus has a consensus rating of “Hold” and a consensus target price of $24.40.

Simulations Plus Trading Up 0.4%

SLP opened at $13.04 on Friday. The stock has a market cap of $262.76 million, a PE ratio of -4.17 and a beta of 1.19. Simulations Plus has a 1 year low of $11.09 and a 1 year high of $36.45. The stock’s 50 day simple moving average is $12.48 and its 200-day simple moving average is $15.97.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.08. The business had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $21.66 million. Simulations Plus had a positive return on equity of 16.48% and a negative net margin of 77.96%. Equities analysts forecast that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Simulations Plus

Large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in Simulations Plus in the second quarter valued at $25,000. Quarry LP bought a new stake in Simulations Plus in the third quarter valued at $28,000. CWM LLC grew its position in Simulations Plus by 3,729.1% in the third quarter. CWM LLC now owns 2,106 shares of the technology company’s stock valued at $32,000 after acquiring an additional 2,051 shares during the period. Farther Finance Advisors LLC bought a new stake in Simulations Plus in the third quarter valued at $40,000. Finally, Caitong International Asset Management Co. Ltd grew its position in Simulations Plus by 343.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock valued at $73,000 after acquiring an additional 3,084 shares during the period. 78.08% of the stock is currently owned by institutional investors.

Key Stories Impacting Simulations Plus

Here are the key news stories impacting Simulations Plus this week:

• Positive Sentiment: Q2 results beat expectations — SLP reported $0.35 EPS vs. $0.27 consensus and revenue of $24.29M vs. $21.66M expected; software revenue grew and management provided supporting slides/press release. Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Management highlights growth drivers & AI opportunity — company commentary and coverage emphasize an improving biosimulation outlook driven by AI adoption, which supports longer-term revenue potential. Simulations Plus jumps on earnings beat, sees AI boosting biosimulation outlook
• Positive Sentiment: Backlog and margin trends supportive — coverage notes backlog growth and expanding margins across software and services, which can underpin future revenue and profitability improvements. Simulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares Soar
• Neutral Sentiment: Full earnings call/transcript and slides now available for deeper diligence — read the call transcript and slide deck for management detail on bookings, segment trends, and AI initiatives. Simulations Plus (SLP) Q2 2026 Earnings Transcript
• Negative Sentiment: FY2026 EPS guidance trimmed — company updated FY26 EPS guidance to $0.75–$0.85 vs. consensus ~$1.01, a clear downward revision that can pressure valuation and near-term sentiment. Guidance coverage
• Negative Sentiment: Analyst target cut and rating — TD Cowen lowered its price target from $19 to $16 and set a “hold,” which reduces near-term upside implied by Street estimates and may temper momentum. Benzinga coverage of TD Cowen note

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.